Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1206 of 6351
-
Letting cancer patients choose their Quit-Smoking method may boost success
Disease control CompletedSmoking cessation has been shown to improve the effectiveness and reduce the morbidity of tobacco-related cancer treatments. We will identify effective smoking cessation strategies for patients who are receiving treatment for tobacco-related cancer. In this trial, patients' prefe…
Phase 2 • Sponsor: Joseph Valentino, MD • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Mayo clinic tests voice recordings to spot hidden heart and lung disease
Diagnosis Recruiting nowThe purpose of this study is to determine the association between patient voice signal characteristics and the presence and severity of pulmonary hypertension in patients referred for elective clinically indicated echocardiography for at Mayo Clinic MN.
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
The 16-Hour fast: does Time-Restricted eating beat calorie counting?
Disease control CompletedA 12-month randomized, controlled, parallel-arm trial, divided into 2 consecutive periods: (1) 6-month weight loss period; and (2) 6-month weight maintenance, will be implemented. Adults with obesity will be randomized to 1 of 3 groups: (1) 8h-TRE, ad libitum food intake from 12p…
Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could a daily pill replace growth hormone shots for children?
Disease control CompletedThis is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.
Phase 2 • Sponsor: Lumos Pharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Eye drops could brighten your night vision
Symptom relief CompletedThe objectives of this study are: * To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD) * To evaluate efficacy of Nyxol to improve visual performance * To evaluate the safety of Nyxol
Phase 3 • Sponsor: Ocuphire Pharma, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
New drug aims to tame rare immune storms
Disease control OngoingThis study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can amniotic tissue ease arthritic knees? large trial completed
Symptom relief CompletedThis study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the knee.
Phase 3 • Sponsor: Organogenesis • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
New drug shows promise for stem cell transplant complication
Disease control OngoingThis phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a drug that calms inflammation ease chronic sinusitis?
Disease control CompletedPrimary Objective: To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on computerized tomography (CT) scan in the dupilumab group only Secondary Objectives: * To evaluate the efficacy of dupilumab as assessed by the reduction a…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
One-Hour heart attack test could save lives and slash ER wait times
Diagnosis OngoingThe PRESC1SE-MI study compares two algorithms for triage of patients presenting with chest pain and symptoms of heart attack (myocardial infarction) to the emergency department. Both algorithms are recommended by the European Society of Cardiology: the 0/3-hour algorithm and the …
Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo aims to fight Hard-to-Treat sarcomas
Disease control OngoingThis phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies,…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Weekly insulin shot could replace daily injections for diabetes
Disease control CompletedThis study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compar…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for hard-to-treat myeloma: three-drug combo enters phase 2 trial
Disease control Recruiting nowThis phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzyme…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a common painkiller reduce breast cancer risk?
Prevention CompletedThe primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
Phase 2 • Sponsor: Alison Stopeck • Aim: Prevention
Last updated Jul 19, 2026 00:00 UTC
-
Tailored smoking treatment shows promise for vulnerable patients
Disease control CompletedThis phase 3 randomized controlled trial will test Metabolism-Informed Smoking Treatment (MIST), a precision approach to smoking treatment that biologically tailors medication selection to nicotine metabolism.
Phase 3 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Could a light cap ease autism symptoms in young children?
Symptom relief CompletedThe hypothesis of the study is that photobiomodulation reduces symptoms of autism. Participants will be children between the ages of 2 and 6, who have been diagnosed with moderate to severe autism. Transcranial photobiomodulation will be administered to the children in the experi…
Sponsor: JelikaLite LLC • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Can a device replace pills for opioid withdrawal?
Disease control CompletedThe Bridge Device (BD) is a neuromodulator medical device that has been cleared by the FDA for Opioid Use Disorder (OUD) treatment. Importantly, medical devices reviewed by the FDA are cleared (based on safety) rather than approved (based on efficacy), which means the BD did not …
Phase 2/3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Wireless pacemaker shows promise in large trial
Disease control Completedprospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug hopes to boost brain recovery after stroke
Disease control CompletedStroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment. The purpose of this study is to evaluate the safety and efficacy of elezanumab and assess …
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Targeted drug shows promise for Hard-to-Treat bladder cancers
Disease control OngoingThis phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controll…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC